

# Amniotics AB postpones the publication of the interim report for the second quarter until 31 August 2023

**Amniotics has decided to postpone the publication of the interim report for the second quarter. The previously announced date for publication was Friday, 18 August. The new date for publication is Thursday, 31 August.**

The postponement is due to administrative reasons.

**For more information please contact**

---

Marcus Larsson  
CEO, Amniotics AB  
Phone: +46 (0) 763 0840 91  
Email: [ml@amniotics.com](mailto:ml@amniotics.com)

## **About Amniotics**

---

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at [www.amniotics.com](http://www.amniotics.com).

## **Attachments**

---

[Amniotics AB postpones the publication of the interim report for the second quarter until 31 August 2023](#)